author-photo

Thomas Powles

Queen Mary University of London
St Bartholomew's Hospital
Royal Free Hospital

798

Papers

35267

Citations

Citation Trend

Filter By

Papers (798) Sort By

Journal Conference Others

Patient outcomes following disease progression with enfortumab-vedotin (EV) in metastatic urothelial carcinoma (mUC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.

2021 Nature
Show All
- Source
- Cite
- Save
Citations (21)
First-line treatments for cisplatin-eligible patients with metastatic urothelial carcinoma: A meta-analysis

2021 European Urology
Show All
- Source
- Cite
- Save
Citations (0)
Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
660P Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): Outcomes in subgroups and toxicity update

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Urological Anti-cancer Agents

2021
- Bernadett Szabados
- Thomas Powles
Show All
- Source
- Cite
- Save
Citations (0)
708P PD-L1 as a predictor of survival in patients with metastatic urothelial carcinoma (mUC) from the phase III DANUBE trial of durvalumab (D) or durvalumab plus tremelimumab (D+T) versus standard of care chemotherapy (SoC)

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT188: IMmotion151: updated overall survival (OS) and exploratory analysis of the association of gene expression and clinical outcomes with atezolizumab plus bevacizumab vs sunitinib in patients with locally advanced or metastatic renal cell carcinoma (mRCC)

2021 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)